Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age 18-80 years
• Anterior-circulation large-vessel occlusion involving the intracranial ICA, M1, or proximal/dominant M2
• Eligible for endovascular treatment within 24 hours of last known well
• Baseline NIHSS score ≥6
• Baseline ASPECTS ≥6
• Pre-stroke mRS score 0-1
• Written informed consent provided by the participant or legally authorized representative
Locations
Other Locations
China
Anyang People's Hospital
NOT_YET_RECRUITING
Anyang
Xuanwu Hospital，Capital Medical University
RECRUITING
Beijing
Anji County People's Hospital
RECRUITING
Huzhou
Jiuquan People's Hospital
RECRUITING
Jiuquan
Lishui Central Hospital
RECRUITING
Lishui
Shangqiu First People's Hospitl
RECRUITING
Shangqiu
Suzhou Municipal Hospital of Anhui Province
RECRUITING
Suzhou
Taizhou Enze Medical Center (Group) Enze Hospital
RECRUITING
Taizhou
The Affiliated Hospital of Xuzhou Medical University
RECRUITING
Xuzhou
Yueqing People's Hospital
RECRUITING
Yueqing
Yulin Second People's Hospital
RECRUITING
Yulin
Zhangpu County Hospital
RECRUITING
Zhangzhou
Zibo Central Hospital
RECRUITING
Zibo
Contact Information
Primary
Xunming Ji, PhD/MD
jixm@ccmu.edu.cn
01083198962
Backup
Chuanjie Wu, PhD/MD
Time Frame
Start Date: 2026-09-06
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 204
Treatments
Experimental: Anisodine Hydrobromide Group
Participants will receive anisodine hydrobromide combined with endovascular thrombectomy.
Placebo_comparator: Anisodine Hydrobromide placebo
Participants will receive placebo combined with endovascular thrombectomy.
Related Therapeutic Areas
Sponsors
Leads: Capital Medical University